Kevin Patrick Danahy Sells 20,000 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock

Pulse Biosciences, Inc (NASDAQ:PLSE) insider Kevin Patrick Danahy sold 20,000 shares of the company’s stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $25.20, for a total transaction of $504,000.00. Following the completion of the transaction, the insider owned 43,298 shares of the company’s stock, valued at approximately $1,091,109.60. The trade was a 31.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Kevin Patrick Danahy also recently made the following trade(s):

• On Monday, February 9th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The shares were sold at an average price of $21.45, for a total transaction of $429,000.00.

Pulse Biosciences Stock Performance

Shares of NASDAQ:PLSE opened at $23.40 on Friday. The company has a 50-day simple moving average of $15.17 and a 200-day simple moving average of $15.72. Pulse Biosciences, Inc has a one year low of $12.56 and a one year high of $26.30. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of -20.71 and a beta of 1.77.

Analysts Set New Price Targets

Several research firms have recently commented on PLSE. Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Thursday, January 22nd. Mizuho set a $30.00 price objective on shares of Pulse Biosciences in a research report on Friday, February 6th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $26.00.

Hedge Funds Weigh In On Pulse Biosciences

Large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets lifted its stake in shares of Pulse Biosciences by 63.6% in the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after purchasing an additional 680 shares during the period. Tower Research Capital LLC TRC grew its position in Pulse Biosciences by 275.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after buying an additional 2,156 shares during the period. Russell Investments Group Ltd. increased its holdings in Pulse Biosciences by 44.0% in the third quarter. Russell Investments Group Ltd. now owns 4,487 shares of the company’s stock valued at $79,000 after buying an additional 1,372 shares in the last quarter. KLP Kapitalforvaltning AS lifted its position in shares of Pulse Biosciences by 136.0% during the 3rd quarter. KLP Kapitalforvaltning AS now owns 5,900 shares of the company’s stock valued at $104,000 after acquiring an additional 3,400 shares during the period. Finally, AlphaQuest LLC lifted its position in shares of Pulse Biosciences by 184.5% during the 2nd quarter. AlphaQuest LLC now owns 8,864 shares of the company’s stock valued at $134,000 after acquiring an additional 5,748 shares during the period. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.